This study was initiated in June 1999 with a comprehensive computer search through the MEDLINE and EMBASE databases (Silverplatter, WinSPIRS 4·0) of the medical literature published after 1993. The search strategy was a combination of free text (PET and lung and cancer) and systematic search terms from Thesaurus (tomographyemission-computed; emission-tomography and lungneoplasm; carcinoma-non-small-cell lung; carcinomasmall-cell; lung-cancer). To avoid missing relevant literature, the
ReviewPositron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review
Section snippets
Assessment of methodological quality
The search strategy retrieved about 300 references. Of these, 190 were relevant for the purpose of this study, and we reviewed these to assess eligibility for further analysis. Articles selected for inclusion met the following criteria: original work assessing the diagnostic performance of FDGPET in the investigation of lung cancer; adequate description of methods and results; and a study population of more than ten patients. A total of 55 studies met these criteria (46 with dedicated PET and
Data analysis
Most studies describe only sensitivity and specificity (nosographic probabilities), because these are most important ways of assessing the diagnostic performance of a new test. But in the interpretation of the test result, positive and negative predictive values (diagnostic probabilities) are important to the clinician. Nosographic probabilities are deemed to be relatively independent of the disease prevalence, whereas diagnostic probabilities depend on the prevalence of the disease in the
Descriptive analysis
Of the 55 articles eligible for further analysis, 46 addressed dedicated PET (see Webtable 1 on The Lancet Oncology website http://oncology.thelancet.com)15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 and nine gammacamera PET (see Webtable 2, as above).61, 62, 63, 64, 65, 66, 67, 68, 69 Of these studies, 19 were not eligible for the quantitative analysis, owing
Discussion
From this systematic assessment of the present evidence on PET in the diagnosis and staging of NSCLC, we found that there were no randomised studies, and many of the existing studies had several flaws in the methodology. Nevertheless, the conclusions of the studies were quite consistent and apparently independent of the methodological quality.
Before reaching any conclusions, we shall discuss the following three questions, which are the backbone of the process of evidence-based decision-making.14
Conclusion
Introduction of PET as a routine diagnostic tool in the investigation of NSCLC would make it possible - with one examination - to decide whether a pulmonary nodule is malignant or benign, and to identify the stage of a potential cancer. This can be done with higher accuracy than with the current non-invasive methods. If PET is applied to a population of patients with a high prevalence of NSCLC, the PET result will in most cases be valid enough for decisions to be made on the future management
Search strategy and selection criteria
References (74)
- et al.
Incidence of lung cancer in Denmark: historical and actual status
Lung Cancer
(2000) - et al.
Applications of PET in lung cancer
Semin Nucl Med
(1998) - et al.
Positron emission tomography in lung cancer
Ann Thorac Surg
(1998) - et al.
Positron emission tomographic imaging with flurodeoxyglucose is efficacious in evaluating malignant pulmonary disease
J Thorac Cardiovasc Surg
(1999) - et al.
Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions
Chest
(1998) - et al.
Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan
Chest
(1997) - et al.
Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy
Chest
(1996) - et al.
PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk-benefit analysis
Chest
(1995) - et al.
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
Ann Thorac Surg
(1995) - et al.
Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)
J Thorac Cardiovasc Surg
(1995)
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
Ann Thorac Surg
Selective use of PET scan in the preoperative staging of NSCLC
Lung Cancer
Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer
Chest
Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography
J Thorac Cardiovasc Surg
Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma
Chest
Staging non-small cell lung cancer by whole-body positron emission tomographic imaging
Ann Thorac Surg
Whole-body 18Fflurodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
Lancet
FDG SPECT in patients with lung masses
Chest
Costeffectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma
Acad Radiol
Bronchogenic carcinoma
Lungesygdomme
Positron emission tomography: methods and instrumentation
PET scans approved for detecting metastatic non-smallcell lung cancer
J Natl Cancer Inst
New techniques catch lung cancers earlier
J Natl Cancer Inst
Meta-analysis: bias in location and selection of sudies
BMJ
Cochrane Handbook
MDRC Technology Assessment Program: PET Report
Rationel Klinik, Evidensbaserede diagnostiske og terapeutiske beslutninger (Rational diagnosis and treatment
Evidence based medicine: how to practice and teach EBM
Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma
J Nucl Med
Localized form of bronchioloalveolar carcinoma: FDG PET findings
AJR Am J Roentgenol
Prospective investigation of positron emission tomography in lung nodules
J Clin Oncol
Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum
J Nucl Med
Controlled prospective study of positron emission tomography using glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules
Br J Surg
Pulmonary abnormalities and PET data analysis: a retrospective study
Radiology
Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
Eur Respir J
Cited by (148)
Does Tumor FDG-PET Avidity Represent Enhanced Glycolytic Metabolism in Non-Small Cell Lung Cancer?
2020, Annals of Thoracic SurgeryPositron Emission Tomography
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth Edition